HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elizabeth Orr

Washington, DC
Elizabeth Orr focuses on legal affairs affecting the medical device industry. Before joining Informa in September 2015, she spent three years spent reporting on all things device-related at FDANews. She remains fascinated by the ever-changing master class on technology, government regulations, advances in health care and more that is covering the device industry. Elizabeth’s past employers include DecisionHealth (formerly UCG); the Society of Interventional Radiology; and the Washington Examiner.  A graduate of the College of Journalism at the University of Maryland College Park, she lives in Arlington, Va., with her husband and children.
Set Alert for Articles By Elizabeth Orr

Latest From Elizabeth Orr

CooperVision Nabs Approval On Pediatric Contact Lens

A newly approved contact lens from CooperVision promises to slow the progression of nearsightedness when prescribed to children aged 8 to 12.

Approvals Ophthalmology

FDA Advisory Panel Debates Science On Human Adverse Biological Reactions To Metal-Containing Devices

US FDA scientists and immunological experts discussed the latest science regarding patients’ biological reactions to metal implants and mercury in dental amalgam at a 13-14 November agency advisory committee meeting. The get-together was held to determine what additional actions the FDA can take to make sure certain patients are protected from immunological risks of the implants. The panel ultimately backed a transition away from mercury amalgam dental fillings and pushed for more research into risks associated with metal implants.

Safety FDA

VIVA 2019: New Paclitaxel Data Shows Consistent Mortality Signal, No Clear Cause

Research investigating outcomes in patients treated with paclitaxel-coated devices demonstrated a consistent if modest mortality signal when compared to bare-metal stents. However, the signal was not seen in real-world data, and some researchers question whether the signal might stem from problems in the original trials. 

Research & Development Safety

Software Issue Brings Recall Of Zimmer ROSA

Zimmer Biomet has issued a recall on its ROSA Brain 3.0 software platform due to a software issue that could cause patient injury.

Recalls Safety

VIVA 2019: 4-Year Data Shows Success For Medtronic’s In.Pact Admiral DCB

An ongoing trial of Medtronic’s In.Pact Admiral paclitaxel-coated balloon found a four-year survival rate in line with what would be expected for the patient population and a relatively low rate of complications.

Cardiovascular Clinical Trials

Warning Letter Close-Outs – October 2019

The US FDA released two device-related close-out letters in October.

Device Warning Letters FDA
See All